How phenytoin causes osteomalacia
Reading File
Finding Sources
Finding Sources
Searching PubMed
phenytoin osteomalacia vitamin D
Reading File
Reading File
Finding Sources
Excellent - I now have rich mechanistic detail from Goodman & Gilman and Katzung. Let me compile the full answer.
Phenytoin-Induced Osteomalacia: Mechanism
Phenytoin causes osteomalacia through multiple, overlapping mechanisms that all converge on disrupted calcium and bone metabolism.
1. Induction of Hepatic CYP Enzymes -> Accelerated Vitamin D Catabolism
This is the primary mechanism. Phenytoin is a potent inducer of cytochrome P450 enzymes (especially CYP3A4, CYP2C9). This upregulates hepatic hydroxylation pathways that convert:
- 25-hydroxyvitamin D (calcidiol) -> inactive polar metabolites (24,25-dihydroxyvitamin D and other oxidized products)
- 1,25-dihydroxyvitamin D (calcitriol) -> inactive metabolites
The net result is a marked reduction in circulating active vitamin D, particularly 25-OH-D and 1,25-(OH)₂-D. This has been well-documented in patients on long-term phenytoin therapy.
- Goodman & Gilman's, Toxicity section: osteomalacia "has been attributed to both altered metabolism of vitamin D and inhibition of intestinal absorption of Ca²⁺."
- Katzung's Basic and Clinical Pharmacology, 16th Ed.: "Long-term use may also result in abnormalities of vitamin D metabolism, leading to osteomalacia."
2. Inhibition of Intestinal Calcium Absorption
Even independent of vitamin D effects, phenytoin directly impairs intestinal absorption of Ca²⁺. Active transcellular calcium transport in the gut depends on calcitriol-stimulated calbindin synthesis; phenytoin disrupts this at multiple levels, reducing net calcium uptake.
3. Increased Metabolism of Vitamin K + Reduction of Vitamin K-Dependent Bone Proteins
Phenytoin also accelerates catabolism of vitamin K. This is clinically important because:
- Osteocalcin (bone Gla protein) and matrix Gla protein (MGP) require vitamin K-dependent gamma-carboxylation to function normally in calcium binding and bone mineralization
- Reduced levels of these proteins impair the deposition of calcium into bone matrix (osteoid)
This is the reason why osteomalacia due to phenytoin does not always respond to vitamin D supplementation alone - the vitamin K-dependent pathway is a parallel, independent defect. (Goodman & Gilman's)
4. Secondary Hyperparathyroidism
The resulting hypocalcemia (from reduced gut absorption and poor bone mineralization) stimulates secondary hyperparathyroidism. PTH increases bone resorption, worsening bone density and contributing to the clinical picture of osteomalacia/rickets in children and osteoporosis/osteomalacia in adults.
Biochemical Signature
| Lab Finding | Cause |
|---|---|
| Low 25-OH-D and 1,25-(OH)₂-D | CYP induction -> accelerated catabolism |
| Hypocalcemia | Reduced gut absorption + poor bone mineral |
| Elevated alkaline phosphatase | Osteoblast hyperactivity (marker of osteomalacia) |
| Elevated PTH (secondary) | Response to hypocalcemia |
| Prolonged prothrombin time (sometimes) | Vitamin K depletion |
Clinical Notes
- Other enzyme-inducing antiepileptics (phenobarbital, carbamazepine, primidone) share the same mechanism and can cause the same complication.
- Carbonic anhydrase inhibitors (e.g., acetazolamide) potentiate phenytoin/phenobarbital-induced osteomalacia when used together. (Brenner & Rector's The Kidney)
- Long-term therapy patients should be monitored with serum 25-OH-D, calcium, phosphate, and alkaline phosphatase.
- Treatment includes vitamin D supplementation (often high-dose), though this may be partially insufficient if vitamin K deficiency is contributing.
Summary of the mechanism in sequence:
Phenytoin induces hepatic CYP enzymes -> accelerated breakdown of vitamin D to inactive metabolites -> reduced circulating calcitriol -> decreased intestinal calcium absorption + impaired osteoid mineralization -> hypocalcemia and elevated ALP (osteomalacia). Concurrently, phenytoin depletes vitamin K -> reduced gamma-carboxylation of bone Gla proteins -> further impaired bone mineralization independent of the vitamin D axis.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics (11th/13th Ed.), Katzung's Basic and Clinical Pharmacology (16th Ed.), Rheumatology 2-Volume Set (2022, Elsevier)
How phenytoin causes megaloblastic anemia
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have detailed content from Harrison's, Henry's Clinical Diagnosis, Robbins, Katzung, and Lippincott. Here is the complete answer:
How Phenytoin Causes Megaloblastic Anemia
The Core Mechanism: Folate Deficiency
Phenytoin causes megaloblastic anemia through folate deficiency, not vitamin B12 deficiency. The dominant mechanism is impaired folate absorption in the gut, with additional contributing factors.
1. Drug-Induced Malabsorption of Pteroylpolyglutamate
Dietary folate exists predominantly as folylpolyglutamates (pteroylpolyglutamate). For absorption to occur, intestinal conjugases (pteroylpolyglutamate hydrolases) must first cleave the polyglutamate chain into absorbable monoglutamate forms, which are then taken up in the proximal jejunum and converted to 5-methyltetrahydrofolate (the circulating transport form).
Phenytoin inhibits this deconjugation process, preventing the cleavage of pteroylpolyglutamate into absorbable monoglutamates. The result is that dietary folate passes through the gut unabsorbed.
Henry's Clinical Diagnosis and Management by Laboratory Methods: "The problem appears to be a drug-induced malabsorption of pteroylpolyglutamate."
Robbins Pathologic Basis of Disease: "Certain drugs, particularly the anticonvulsant phenytoin and oral contraceptives, interfere with [folate] absorption."
2. The Exact Mechanism Is Not Fully Defined
Harrison's Principles of Internal Medicine acknowledges frankly that while patients on long-term phenytoin develop low serum and red cell folate levels, "the exact mechanism is unclear." Several proposed mechanisms exist in the literature:
| Proposed Mechanism | Status |
|---|---|
| Inhibition of intestinal pteroylpolyglutamate hydrolase (deconjugase) | Most widely accepted |
| Interference with folate enterohepatic circulation | Possible contributor |
| Direct inhibition of folate transport across intestinal mucosa | Proposed but less established |
| CYP induction increasing folate catabolism | Debated |
Harrison's (22nd Ed.), Antifolate Drugs section
3. Downstream Effect: Impaired DNA Synthesis -> Megaloblastic Changes
Once folate stores become depleted (body reserves last only weeks to months), the resulting deficiency of tetrahydrofolate (THF) cofactors impairs:
- Thymidylate synthesis (dTMP from dUMP) - mediated by 5,10-methyleneTHF
- Purine synthesis - requiring 10-formylTHF
- Methionine regeneration - requiring 5-methylTHF
All three are needed for DNA synthesis. In rapidly dividing cells like erythroid precursors, DNA synthesis is blocked while RNA and protein synthesis continue, causing the classic "nuclear-cytoplasmic dissociation" - cells grow large but cannot divide normally, producing megaloblasts.
Lippincott Illustrated Reviews Pharmacology: phenytoin and phenobarbital cause megaloblastic anemia by reducing folate absorption; "a primary result of folic acid deficiency is megaloblastic anemia (large-sized red blood cells, characterized by an increase in mean corpuscular volume [MCV])."
4. Clinical Features and Important Distinctions
| Feature | Phenytoin-induced (folate deficiency) |
|---|---|
| Blood film | Macro-ovalocytes, hypersegmented neutrophils |
| MCV | Elevated (>100 fL) |
| Serum folate | Low |
| Red cell folate | Low (more reliable chronic marker) |
| Serum homocysteine | Elevated |
| Serum methylmalonic acid (MMA) | Normal (distinguishes from B12 deficiency) |
| Neurological deficits (subacute combined degeneration) | Absent (unlike B12 deficiency) |
| Response to folate supplementation | Yes |
Critical clinical point: Folate supplementation corrects the anemia, but folate should not be given blindly before ruling out B12 deficiency - folate can partially correct the blood picture of B12 deficiency while allowing the neurological damage (subacute combined degeneration of spinal cord) to progress silently. (Robbins)
5. Why Megaloblastic Anemia Is Relatively Rare Despite Folate Deficiency Being Common
Katzung notes that while "long-term therapy with phenytoin also can cause folate deficiency, it only rarely causes megaloblastic anemia." This is because:
- The degree of folate depletion is usually modest
- Patients on adequate diets may partially compensate
- Frank megaloblastic anemia requires a significant fall in folate stores
Most patients on phenytoin show only macrocytosis or low serum/red cell folate without full-blown megaloblastic anemia. (Katzung's Basic and Clinical Pharmacology, 16th Ed.)
6. Other Antiepileptics with the Same Effect
Phenobarbital and primidone cause the identical picture by the same mechanism (malabsorption of pteroylpolyglutamate). Carbonic anhydrase inhibitors and oral contraceptives can also impair folate deconjugation. (Henry's Clinical Diagnosis)
In summary: Phenytoin -> inhibits intestinal pteroylpolyglutamate hydrolase (deconjugase) -> impaired absorption of dietary polyglutamate folate -> reduced circulating 5-methylTHF -> deficient THF cofactors -> impaired DNA synthesis in rapidly dividing erythroid precursors -> megaloblastic anemia. The anemia responds to folate supplementation, no neurological deficits occur (unlike B12 deficiency), and serum MMA remains normal.
Sources: Harrison's Principles of Internal Medicine 22E; Henry's Clinical Diagnosis and Management by Laboratory Methods; Robbins, Cotran & Kumar Pathologic Basis of Disease; Katzung's Basic and Clinical Pharmacology 16th Ed.; Lippincott Illustrated Reviews Pharmacology
This is a shared conversation. Sign in to Orris to start your own chat.